These patients struggle with runaway bones. Finally there’s hope
The FDA approved two new treatments for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder. Regeneron's garetosmab (Pasatru) and Mirum's zilurgisertib (Atebrioz) reduce abnormal bone growth. FOP affects about 900 people worldwide, with limited mobility and shortened lifespans. Trials for pediatric use are ongoing.
How this was made

The 30-second read
Why it matters
Regeneron's approval introduces a novel therapy for a disease with no prior treatments, potentially driving stock appreciation and encouraging further investment in rare‑disease pipelines.
Market read
New FDA approvals for rare‑disease drugs provide a clear catalyst for Regeneron and signal broader biotech sector momentum.
What to watch
Limited patient pool (≈900 cases) may cap revenue, and reimbursement uncertainty could dampen impact.
Background
The article describes recent FDA approvals of two drugs for the ultra‑rare disease FOP: garetosmab by Regeneron and zilurgisertib by Mirum, and discusses patient stories and scientific background.
Ticker impact
FDA approved garetosmab (Pasatru), a monoclonal antibody made by Regeneron for adults with fibrodysplasia ossificans progressiva (FOP).
likely upward pressure as investors price in the new indication.
First‑time FDA approval for a rare disease drug provides a clear revenue opportunity and validates Regeneron's R&D pipeline.
Market effects
Boosts biotech and rare‑disease therapeutic sector as investors see new FDA approvals as catalyst.
Positive for US biotech equities and related ETFs.
Highlights potential for similar rare‑disease treatments worldwide.
Counterpoint
Approval may be priced in already; market could be disappointed if sales ramp slower than expected.
Key entities
- companyRegeneron Pharmaceuticals
US biotech company that received FDA approval for garetosmab.
- companyMirum Pharmaceuticals
Biotech firm that received FDA approval for zilurgisertib.
- regulatorFDA
U.S. Food and Drug Administration that granted the approvals.




